Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease

Journal of the American Society of Nephrology

Volumn 16, Issue 6, 2005, Pages 1537-1538

  Tuttle, Katherine R ^a,b  

^a SACRED HEART MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; OSTEOPONTIN; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; STREPTOZOCIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; EDITORIAL; EPIDEMIC; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMMUNOLOGY; KIDNEY FAILURE; KIDNEY METABOLISM; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ANIMAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; MOUSE; NOTE; RAT;

ANIMALS; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; HUMANS; INDOLES; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MALEIMIDES; MICE; MODELS, ANIMAL; PROTEIN KINASE C; RATS;

EID: 26944433131     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005040393     Document Type: Editorial

References (19)

1. United States Renal Data System: Annual Data Report: Incidence and prevalence, 2001. Am J Kidney Dis 38: S37-S52, 2001
2. United States Renal Data System: Annual Data Report: Incidence and prevalence, 2004. Am J Kidney Dis 45: S77-S80, 2004
3. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795-808, 1999
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995
7. United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
11. Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE: Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental nephropathy. J Am Soc Nephrol 16: 1654-1660, 2005
12. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH: Intracellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16: 1711-1722, 2005
13. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54: 343-352, 1998
14. Nikolic-Paterson DJ, Atkins RC: The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16[Suppl 5]: 3-7, 2001
15. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56: 1627-1637, 1999
16. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C beta inhibition. Am J Kidney Dis 42: 456-465, 2003
17. Park CW, Kim JH, Lee JW, Kin YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK: High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-chiB-dependent. Diabetologia 43: 1544-1553, 2000
18. Okouchi M, Okayama N, Shimizu M, Omi H, Fukutomi T, Itoh M: High insulin exacerbates neutrophil-endothelial cell adhesion through endothelial surface expression of intercellular adhesion molecule-1 via activation of protein kinase C and mitogen-activated protein kinase. Diabetobgia 45: 556-569, 2002
19. Booth G, Stalker TJ, Lefer AM, Scalia R: Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 51: 1556-1564, 2002